BILLERICA, Mass. — Quanterix Corporation (NASDAQ: QTRX), a leading provider of ultra-sensitive research products and high-definition diagnostics, announced today that its Simoa® phospho-Tau 217 (p-Tau 217) blood test has been granted Breakthrough Device designation by the U.S. Food and Drug Administration (FDA) as an aid in diagnostic evaluation of Alzheimer’s...
Latest News
London, UK – Researchers have developed a revolutionary biosensor using terahertz (THz) waves that can detect skin cancer with exceptional sensitivity, potentially paving the way for earlier and easier diagnoses. Published in the IEEE Transactions on Biomedical Engineering, the study presents a significant advancement in early cancer detection, thanks to...
London, UK – Research on thousands of proteins measured from a drop of blood demonstrates the ability of proteins to predict the onset of many diverse diseases. The research, published today (22 July 2024) in Nature Medicine, was carried out as part of an international research partnership between GSK, Queen...
SECAUCUS, N.J. — Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, and Broad Clinical Labs, the world expert in whole genome sequencing (WGS), today announced a research collaboration designed to demonstrate the clinical value of WGS as a first-line genetic test for postnatal diagnosis of developmental delay disorders. The...
MADISON, N.J. — Quest Diagnostics scientists will present results of three studies revealing the effect of genomic abnormalities on the diagnosis and treatment of chronic myeloid leukemia (CML) and prostate cancer during the 45th Annual Meeting of the American Society of Clinical Oncology (ASCO), scheduled for May 29 through June...
CHICAGO, Illinois — Quetzal Therapeutics, a biopharmaceutical company specializing in developing transformative treatments for rare diseases, announced the initiation of a pivotal Phase III clinical trial of QTX-2101, an investigational oral arsenic trioxide capsule. The trial will evaluate the efficacy, safety, and pharmacokinetics of QTX-2101, as a potential new treatment for acute promyelocytic leukemia...
More than half of the people with rare diseases and their caregivers, asked in a survey, were undecided or less than willing to be vaccinated for COVID-19 if a vaccine was approved under emergency use authorization instead of the routine process, the EveryLife Foundation for Rare Disease reports. These findings highlight the need for...
SOUTH SAN FRANCISCO, Calif. – Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the positive outcome of its pre-planned safety analysis conducted by an independent data and safety monitoring board (iDSMB)...
SOUTH SAN FRANCISCO, Calif. –– Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that the last patient has completed their last visit in the company’s pivotal Phase 3 NEAT (Neurological Effects of...
SOUTH SAN FRANCISCO, Calif. – Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the poster presentation of patient-reported walking capacity in children with Ataxia-Telangiectasia (A-T) at the 54th Child Neurology Society (CNS)...